Combination of intramuscular transplantation of autologous mononuclear bone marrow cells with sympathectomy (L2, 3) in patients with peripheral arterial disease(PAD)

In most patients with severe, chronic extremity ischemic diseases, intervention or surgical treatment is often not suitable. Combination of intramuscular transplantation of autologous monocular bone marrow cells (AMBMCs) and sympathectomy (L2, 3) has been proved therapeutically beneficial. We studie...

Full description

Saved in:
Bibliographic Details
Published in:The surgeon (Edinburgh) 2022-06, Vol.20 (3), p.e3-e6
Main Authors: Jo, Il-Su, Kim, Hyon-Jong, Chae, Myong-Hwan, Kwon, Un-Chol, Ju, Gwang-Hak, Song, Un, Hyon, Chol-Ho, Kim, Il-Su
Format: Article
Language:English
Subjects:
Angiogenesis
Arteriosclerosis obliterans(ASO)
Autologous mononuclear bone-marrow cells
Bone Marrow Cells
Bone Marrow Transplantation
Chronic Disease
Humans
Intramuscular transplantation
Ischemia - surgery
Peripheral Arterial Disease - surgery
Sympathectomy
Thromboangitisobliterans(TAO)
Transplantation, Autologous
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In most patients with severe, chronic extremity ischemic diseases, intervention or surgical treatment is often not suitable. Combination of intramuscular transplantation of autologous monocular bone marrow cells (AMBMCs) and sympathectomy (L2, 3) has been proved therapeutically beneficial. We studied 170 patients (combined group 80, control group 90) with extremity ischemia (TAO, ASO FontaineⅡ,Ⅲ, Ⅳ) between January 2013 and September 2019. In contrast to pre-operation, the walking distance of patients increased significantly (from 61.34 ± 52.23 m to 156.0 ± 32.4 m, p 
ISSN:1479-666X
2405-5840
DOI:10.1016/j.surge.2021.02.005